Navigation Links
Life Sciences Discovery Fund helps launch 3 programs to advance health research and development

SEATTLE, Washington, JUNE 27, 2011 The Life Sciences Discovery Fund (LSDF) today announced awards to three multi-institutional teams to support development of improved therapies and key resources for medical researchers and health-care policymakers. LSDF will allocate up to $8 million among the three programs.

The programs will be led by University of Washington investigators in partnership with collaborators across the state. Dr. David Flum will work with health-care providers, insurers, and information technology experts to create databases of clinical practices, patient outcomes, and medical costs that can be used to assess the comparative effectiveness and cost effectiveness of specific health-care strategies. This work builds upon an LSDF project grant that Dr. Flum received in 2007.

A second program, led by Dr. Michael Schwartz, will develop new human stem cell-based treatments for type 1 diabetes that avoid the problems of tumor formation and immune rejection that have previously limited the use of such therapies. The research team anticipates that their treatment approach can ultimately be applied to other diseases.

The third program, directed by Dr. John Slattery, will establish a system for collection and statewide distribution of human biological specimens required to answer important research questions and ultimately improve disease diagnosis and treatment. The specimens will be linked to biologically relevant data on the donors, and the program will be constructed to protect patient privacy and rights. This program will complement the cancer biospecimen resource that Dr. Peggy Porter of the Fred Hutchinson Cancer Research Center is developing under an LSDF 2009 program grant.

The three awards were made in the 2010 program grant competition, which supports the launch of new collaborative initiatives that address major health problems and position organizations for future competitiveness and leadership.

According to LSDF executive director Lee Huntsman, the new cohort of awards is anticipated to reap health and economic impacts that are broad in both magnitude and scope. "In addition to improving treatment of a specific conditionnamely, type 1 diabetesthese grants will create robust resources to accelerate development of diagnostics and therapies for a multitude of diseases."

Huntsman added that "the grant to Dr. Flum will allow Washington's health-care community to answer vital questions regarding the value of various treatments and determine the best uses of our limited health-care dollars."

The LSDF board of trustees selected the awardees from 11 proposals that were evaluated by national experts convened by the American Association for the Advancement of Science. In a highly competitive two-phase process, proposals were rated on scientific merit and the potential to improve health and health care in Washington and provide statewide economic benefit.

Lura Powell, chair of the LSDF board of trustees, noted that the impact of the new awards would likely be felt throughout Washington. "These grants support cutting-edge research as well as widespread distribution of high-quality specimens and health-care data. Together, they will help ensure that our state maintains its leadership position in medical research and delivery of cost-effective health care."


Contact: Alden Jones
Life Sciences Discovery Fund

Related biology news :

1. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
2. Aerospace sciences meeting to be held Jan. 5-8 in Orlando
3. Natural and social sciences: ICSU embraces the need to work more closely together
4. Energy Biosciences Institue named "Deal of Distinction" by tech-transfer group
5. Elsevier partners with the Royal Netherlands Society for Agricultural Sciences
6. The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen
7. Life Sciences Discovery Fund awards health research program grants
8. Springer expands its portfolio in plant sciences with Phytoparasitica
9. Mycotoxin Research joins Springers life sciences journals program
10. NTU seals global partnerships on environmental sciences R&D
11. The Earth Observatory of Singapore devoted to the study of earth sciences officially opens
Post Your Comments:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology: